Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of Difficult-to-Treat Resistance in Gram-negative Bacteremia on Mortality: Retrospective Analysis of Nationwide Surveillance Data
Kyungmin Huh, Doo Ryeon Chung, Young Eun Ha, et al.
Clinical Infectious Diseases (2020) Vol. 71, Iss. 9, pp. e487-e496
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Key Takeaways From the U.S. CDC’s 2019 Antibiotic Resistance Threats Report for Frontline Providers
Sameer S. Kadri
Critical Care Medicine (2020) Vol. 48, Iss. 7, pp. 939-945
Open Access | Times Cited: 209
Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study
Alexis Tabah, Niccolò Buetti, Quentin Staiquly, et al.
Intensive Care Medicine (2023) Vol. 49, Iss. 2, pp. 178-190
Open Access | Times Cited: 140
Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018–2022
Mark G. Wise, James A. Karlowsky, Naglaa Mohamed, et al.
Journal of Global Antimicrobial Resistance (2024) Vol. 37, pp. 168-175
Open Access | Times Cited: 22
Facilitating Compound Entry as a Means to Discover Antibiotics for Gram-Negative Bacteria
Kristen A. Muñoz, Paul J. Hergenrother
Accounts of Chemical Research (2021) Vol. 54, Iss. 6, pp. 1322-1333
Open Access | Times Cited: 74
Prevalence and Antibiotic Resistance of ESKAPE Pathogens Isolated in the Emergency Department of a Tertiary Care Teaching Hospital in Hungary: A 5-Year Retrospective Survey
Ria Benkő, Márió Gajdács, Mária Matúz, et al.
Antibiotics (2020) Vol. 9, Iss. 9, pp. 624-624
Open Access | Times Cited: 64
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes—Study for Monitoring Antimicrobial Resistance Trends, United States 2015–2017
James A. Karlowsky, Sibylle Lob, Janet Raddatz, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 12, pp. 2112-2120
Open Access | Times Cited: 63
Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance
Matteo Bassetti, Antonio Vena, Chiara Sepulcri, et al.
Antibiotics (2020) Vol. 9, Iss. 9, pp. 632-632
Open Access | Times Cited: 54
Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017
Ahmed Babiker, Lloyd Clarke, Melissa Saul, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 11, pp. e4521-e4530
Open Access | Times Cited: 53
In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020
James A. Karlowsky, Sibylle Lob, C Andrew DeRyke, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 5
Open Access | Times Cited: 29
Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis
Milo Gatti, Cecilia Bonazzetti, Beatrice Tazza, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 9, pp. 1150-1158
Open Access | Times Cited: 19
Proposed amendments regarding the definitions of multidrug-resistant and extensively drug-resistant bacteria
Petros I. Rafailidis, Diamantis P. Kofteridis
Expert Review of Anti-infective Therapy (2021) Vol. 20, Iss. 2, pp. 139-146
Closed Access | Times Cited: 40
The epidemiology of bloodstream infection contributing to mortality: the difference between community-acquired, healthcare-associated, and hospital-acquired infections
Seok Jun Mun, Si‐Ho Kim, Hyoung‐Tae Kim, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 24
MDR/XDR/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?
Federica Cosentino, Pierluigi Viale, Maddalena Giannella
Current Opinion in Infectious Diseases (2023) Vol. 36, Iss. 6, pp. 564-571
Open Access | Times Cited: 14
Risk Factors for Development and Mortality of Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection in a Chinese Teaching Hospital: A Seven-Year Retrospective Study
Luyan Dong, Yingbin Huang, Shengcen Zhang, et al.
Infection and Drug Resistance (2025) Vol. Volume 18, pp. 979-991
Open Access
Using a Difficult-to-treat Resistance Index to Gauge Imbalance between Countries’ Antibiotic Resistance Prevalence and Access to Antibiotics: A Scoping Review and Concept Proposal
Morgan Walker, Emad A. Chishti, Christina Yek, et al.
Clinical Microbiology and Infection (2025)
Closed Access
Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study
Jeffrey R. Strich, Sarah Warner, Yi Ling Lai, et al.
The Lancet Infectious Diseases (2020) Vol. 20, Iss. 10, pp. 1172-1181
Open Access | Times Cited: 33
Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
Eric Wenzler, David A. Butler, Xing Tan, et al.
Clinical Pharmacokinetics (2021) Vol. 61, Iss. 4, pp. 539-552
Open Access | Times Cited: 28
Trends of major antimicrobial resistance phenotypes in enterobacterales and gram-negative non-fermenters from ATLAS and EARS-net surveillance systems: Italian vs. European and global data, 2008-2018
Gian María Rossolini, Marzena Bochenska, Laura Fumagalli, et al.
Diagnostic Microbiology and Infectious Disease (2021) Vol. 101, Iss. 4, pp. 115512-115512
Closed Access | Times Cited: 27
Severe infections caused by difficult-to-treat Gram-negative bacteria
Silvia Dettori, Federica Portunato, Antonio Vena, et al.
Current Opinion in Critical Care (2023) Vol. 29, Iss. 5, pp. 438-445
Open Access | Times Cited: 12
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
James A. Karlowsky, Sibylle Lob, Katherine Young, et al.
BMC Microbiology (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Bloodstream Infections Caused by Carbapenem-Resistant Pathogens in Intensive Care Units: Risk Factors Analysis and Proposal of a Prognostic Score
Giorgia Montrucchio, Andrea Costamagna, Tommaso Pierani, et al.
Pathogens (2022) Vol. 11, Iss. 7, pp. 718-718
Open Access | Times Cited: 17
Management strategies for severe Pseudomonas aeruginosa infections
Hermann Do Rego, Jean‐François Timsit
Current Opinion in Infectious Diseases (2023) Vol. 36, Iss. 6, pp. 585-595
Closed Access | Times Cited: 9
Biofilm Formation, Antibiotic Resistance, and Infection (BARI): The Triangle of Death
Vincenzo Giordano, Peter V. Giannoudis
Journal of Clinical Medicine (2024) Vol. 13, Iss. 19, pp. 5779-5779
Open Access | Times Cited: 3
Antimicrobial susceptibility to polymyxin B and other comparators against Gram-negative bacteria isolated from bloodstream infections in China: Results from CARVIS-NET program
Jingyuan Xi, Peiyao Jia, Ying Zhu, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 15
High Burden of Intestinal Colonization With Antimicrobial-Resistant Bacteria in Chile: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study
Rafael Araos, Rachel M. Smith, Ashley Styczynski, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. Supplement_1, pp. S75-S81
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top